{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:37:56Z","timestamp":1793997476816,"version":"4.8.0"},"reference-count":59,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3729,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p>Levetiracetam is a new antiepileptic drug, structurally and mechanistically dissimilar to other marketed antiepileptic drugs. It is effective in reducing partial seizures in patients with epilepsy, both as adjunctive treatment and as monotherapy. Levetiracetam has many therapeutic advantages for patients with epilepsy. It has favorable pharmacokinetic characteristics (good bioavailability, linear pharmacokinetics, insignificant protein binding, lack of hepatic metabolism, and rapid achievement of steady\u2010state concentrations) and a low potential for drug interactions. Recommended starting dosages are considered to be clinically effective; therefore, patients can have some protection from seizures soon after they begin levetiracetam. The most common adverse effects observed with levetiracetam are mild and include somnolence, asthenia, and dizziness. Clinical experience and data from meta\u2010analyses indicate that levetiracetam is well tolerated, with efficacy comparable or slightly better than that observed with other new antiepileptic drugs. Levetiracetam may be particularly useful in patients who are unresponsive to other antiepileptic drugs, patients receiving drugs with increased potential for drug interactions, or those with hepatic impairment.<\/jats:p>","DOI":"10.1592\/phco.21.17.1375.34432","type":"journal-article","created":{"date-parts":[[2004,6,8]],"date-time":"2004-06-08T12:06:03Z","timestamp":1086696363000},"page":"1375-1388","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Levetiracetam: A Novel Antiepileptic Drug"],"prefix":"10.1002","volume":"21","author":[{"given":"Collin A.","family":"Hovinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01224.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905203402008"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806113382402"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01076.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00166.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0388"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271104"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.6.682"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90581-2"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb05201.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0442"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02126.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199503030-00005"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601183340308"},{"key":"e_1_2_1_16_2","first-page":"149","volume-title":"Tolerance to beneficial and adverse effects of antiepileptic drugs","author":"Mattson R.H.","year":"1986"},{"key":"e_1_2_1_17_2","volume-title":"Keppra (levetiracetam) package insert. Smyrna","author":"UCB Pharma, Inc.","year":"1999"},{"key":"e_1_2_1_18_2","volume-title":"Data on file. Smyrna","author":"UCB Pharma, Inc.","year":"2001"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb04523.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00913.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00410-5"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90768-D"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3565(24)37251-9","article-title":"Antiepilpetogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy","volume":"284","author":"Loscher W.","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00016-3"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00077-1"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)00031-9"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton P.","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.3.411"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00436-O"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005097"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00597-8"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701476"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)00105-2"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.2000.0689"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90855-X"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00052-2"},{"issue":"7","key":"e_1_2_1_37_2","first-page":"S124","article-title":"Single\u2010dose pharmacokinetics of levetiracetam in pediatric patients with partial epilepsy [abstr]","volume":"40","author":"Pellock J.","year":"1999","journal-title":"Epilepsia"},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(24)15285-3","article-title":"In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent","volume":"27","author":"Nicholas J.M.","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"e_1_2_1_39_2","first-page":"S76","article-title":"Mechanism of interaction between ucb L059 and phenytoin [abstr]","volume":"35","author":"Patsalos P.N.","year":"1994","journal-title":"Epilepsia"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6974(96)00010-2"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01278.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00255.x"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00323.x"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00158-3"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0380"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04605.x"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1499-1654.2000.001499.x"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.12.1772"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb02017.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00165.x"},{"key":"e_1_2_1_52_2","volume-title":"Drug topics red book","author":"Cardinale V.","year":"2000"},{"key":"e_1_2_1_53_2","volume-title":"The Cochrane library","author":"Chaisewikul R.","year":"2001"},{"key":"e_1_2_1_54_2","volume-title":"The Cochrane library","author":"Marson A.G.","year":"2001"},{"key":"e_1_2_1_55_2","volume-title":"The Cochrane library","author":"Ramaratnam S.","year":"2001"},{"key":"e_1_2_1_56_2","volume-title":"The Cochrane library","author":"Castillo S.","year":"2001"},{"key":"e_1_2_1_57_2","article-title":"Tiagabine add\u2010on for drug\u2010resistant partial epilepsy","volume":"2","author":"Pereira J.","year":"2001","journal-title":"Cochrane Database of Syst Rev (Online Edit)"},{"key":"e_1_2_1_58_2","volume-title":"The Cochrane library","author":"Jette N.J.","year":"2001"},{"key":"e_1_2_1_59_2","volume-title":"The Cochrane library","author":"Chadwick D.W.","year":"2001"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01251.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.17.1375.34432","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.17.1375.34432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:38:46Z","timestamp":1761039526000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.17.1375.34432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1592\/phco.21.17.1375.34432"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.17.1375.34432","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}